6.9), and lupus/lupus-like syndrome (6.7 [3.5-11.7]; 7.7 [1.4-24.1]; 54.4). No dermatomyositis/polymyositis, polyarteritis nodosa, relapsing polychondritis, or Wegener's granulomatosis events were confirmed; 1 confirmed case each of morphea and scleroderma occurred. Silicone implants did not put subjects at significantly greater risk for any target AEs versus saline implants. The adjusted RRs (90% CIs) for silicone versus saline implants were brain cancer: 
.1]; 24.6), Sjögren syndrome (7.5 [4.1-12.7]; 11.5 [3.1-29.7 ]; 6.9), and lupus/lupus-like syndrome (6.7 [3.5-11.7]; 7.7 [1.4-24 .1]; 54.4). No dermatomyositis/polymyositis, polyarteritis nodosa, relapsing polychondritis, or Wegener's granulomatosis events were confirmed; 1 confirmed case each of morphea and scleroderma occurred. Silicone implants did not put subjects at significantly greater risk for any target AEs versus saline implants. The adjusted RRs (90% CIs) for silicone versus saline implants were brain cancer The most common major complication was major mastectomy flap necrosis (8.1%). The rate of reconstructive failure was 5.6% while that for implant loss was 4.4%. The most common minor complication was minor mastectomy flap necrosis (14.4%). The rates of full thickness and partial thickness nipple necrosis were 4.4% and 7.5%, respectively. Independent risk factors for complications were analyzed. Age greater than 50 (p=0.0276) and implant size greater than 400 mL (p=0.0467) emerged as independent predictors of overall complications. Obesity (p=0.4073), tobacco use (p=0.2749), prior radiation therapy (p=0.4613), and ADM (p=0.5305) were not associated with greater complication rates.
ConClusions:
Immediate, permanent implant reconstruction in NSM provides patients with a "breast in a day" in less than two procedures with a low complication rate.
